secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-07-19T23:59:59+00:00
Accession:  0001104659-24-081162
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq warns Brainstorm Cell Therapeutics of MVLS deficiency; 180 days to comply
--------------------------------------------------------------------------------

- Received Nasdaq deficiency notice on July 18, 2024 for MVLS below $35M minimum.
- Company has until January 14, 2025 to regain compliance by closing at $35M or more for 10 consecutive business days.
- If not compliant by deadline, Nasdaq may delist BCLI common stock; company may appeal.
- No immediate impact on trading; BCLI continues to trade on Nasdaq Capital Market.
- Company intends to monitor and take reasonable measures to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924081162/0001104659-24-081162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924081162/tm2419839d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-081162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer